[144] RESMED INC SEC Filing
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
Michael Farrell reported a proposed sale of 4,991 shares of Common Stock under Rule 144 on 05/07/2026. The form lists an option granted dated 11/21/2019 and shows three prior sales of 4,991 shares on 02/09/2026, 03/09/2026, and 04/07/2026 with dollar figures provided alongside each sale.
Positive
- None.
Negative
- None.
Key Figures
Shares to be sold: 4,991 shares
Option grant date: 11/21/2019
Prior sale 1 proceeds: $1,366,436.48
+3 more
6 metrics
Shares to be sold
4,991 shares
listed under "Securities To Be Sold" dated 05/07/2026
Option grant date
11/21/2019
appears on the securities-to-be-sold line as "Option Granted - 11/21/2019"
Prior sale 1 proceeds
$1,366,436.48
sale on 02/09/2026 for 4,991 shares (figure listed adjacent)
Prior sale 2 proceeds
$1,252,901.71
sale on 03/09/2026 for 4,991 shares (figure listed adjacent)
Prior sale 3 proceeds
$1,125,486.47
sale on 04/07/2026 for 4,991 shares (figure listed adjacent)
Broker listed
Fidelity Brokerage Services LLC
broker entry alongside Common stock on form (address shown)
Key Terms
Rule 144, Option Granted, Compensation
3 terms
Rule 144 regulatory
"reported a proposed sale of 4,991 shares under Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Option Granted financial
"Option Granted - 11/21/2019 shown on the securities-to-be-sold line"
Compensation financial
"the securities-to-be-sold entry is labeled "Compensation""